Emily Leproust Sells 2,423 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 2,423 shares of the firm’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $46.43, for a total value of $112,499.89. Following the sale, the chief executive officer owned 860,629 shares in the company, valued at approximately $39,959,004.47. The trade was a 0.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Twist Bioscience Stock Down 6.1%

NASDAQ TWST traded down $2.93 on Tuesday, reaching $45.40. The company had a trading volume of 851,196 shares, compared to its average volume of 1,381,620. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $57.88. The firm has a 50-day moving average of $43.92 and a 200-day moving average of $34.80. The firm has a market capitalization of $2.78 billion, a PE ratio of -35.47 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The firm had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company’s quarterly revenue was up 16.9% compared to the same quarter last year. On average, equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Stifel Financial Corp grew its stake in shares of Twist Bioscience by 3.6% in the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after purchasing an additional 271 shares during the last quarter. D.A. Davidson & CO. boosted its holdings in Twist Bioscience by 1.2% during the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after buying an additional 305 shares in the last quarter. CWM LLC grew its position in Twist Bioscience by 9.4% in the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after buying an additional 407 shares during the last quarter. California State Teachers Retirement System grew its position in Twist Bioscience by 0.8% in the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after buying an additional 442 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after buying an additional 442 shares in the last quarter.

Analyst Ratings Changes

A number of equities analysts have commented on TWST shares. Barclays upped their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Evercore boosted their price target on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. Robert W. Baird set a $50.00 price objective on Twist Bioscience in a research note on Tuesday, February 3rd. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $45.88.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.